China In 2018: Watch Out For AI, CAR-T And Biotech Unicorns
Executive Summary
Armed with massive amounts of data, China is poised to make a dent in big data-driven innovation and artificial intelligence applications including smart health. A policy push to encourage the development of novel drugs also means there may be more biotech unicorns and innovative therapies to attract investment inflows.
You may also be interested in...
2017 A Takeoff Year For China Drug Approvals?
2017 may become a banner year for the China FDA as the agency officially joined the ICH process and began aligning more closely with the US FDA, approving over 25 innovative new drugs so far with an increasing focus on treatments for cancer, hepatitis and orphan diseases.
Pharma-BAT Digital Health Tango In China: Will It Pay Off?
China's internet giants Baidu, Alibaba and Tencent, collectively called BAT, are increasingly tapping into digital health to benefit from recent policy changes, and 2017 saw pharma companies eagerly jump onboard to share the potential gains.
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Data from a Phase I trial testing the CAR-T therapy bb2121 in in heavily treated patients with relapsed refractory multiple myeloma were encouraging, driving bluebird's stock up 10%.